Double-Blind, Crossover Study of Clonidine and Levetiracetam in Tourette Syndrome

Erika Finanger, Christina M. Morris, Harvey S. Singer

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

We compared the efficacy of clonidine and levetiracetam for treating tics in Tourette syndrome. Twelve subjects were enrolled; 10 (ages 8-27 years) with moderate to moderately severe tics completed a 15-week randomized, double-blind, flexible-dose crossover protocol. Initial medication doses were clonidine (0.05 mg, twice daily) or levetiracetam (10 mg/kg/day, divided twice daily). Doses were adjusted weekly, based on telephone assessment. The primary outcome measure was baseline-to-posttreatment (6-week) change in Total Tic Score of the Yale Global Tic Severity Scale. Secondary outcome measures included total Yale Global Tic Severity Scale and Clinical Global Impression scores and behavioral measures. The mean Total Tic Score improved significantly from baseline to posttreatment with clonidine (25.2 versus 21.8) compared with levetiracetam (22.7 versus 23.6) (P = 0.013). The mean total Yale Global Tic Severity Scale and Clinical Global Impression score did not change. For levetiracetam, no changes occurred in any scales. No significant change occurred in any secondary behavioral outcome measures for either group. The most commonly reported side effects were, for clonidine, sedation (n = 5), and for levetiracetam, irritability (n = 4). Treatment with clonidine, but not levetiracetam, resulted in a small reduction in Total Tic Score, with an effect size of 0.57.

Original languageEnglish (US)
Pages (from-to)420-425
Number of pages6
JournalPediatric Neurology
Volume40
Issue number6
DOIs
StatePublished - Jun 2009
Externally publishedYes

Fingerprint

etiracetam
Tics
Tourette Syndrome
Clonidine
Double-Blind Method
Cross-Over Studies
Outcome Assessment (Health Care)
Telephone

ASJC Scopus subject areas

  • Clinical Neurology
  • Pediatrics, Perinatology, and Child Health
  • Developmental Neuroscience
  • Neurology

Cite this

Double-Blind, Crossover Study of Clonidine and Levetiracetam in Tourette Syndrome. / Finanger, Erika; Morris, Christina M.; Singer, Harvey S.

In: Pediatric Neurology, Vol. 40, No. 6, 06.2009, p. 420-425.

Research output: Contribution to journalArticle

Finanger, Erika ; Morris, Christina M. ; Singer, Harvey S. / Double-Blind, Crossover Study of Clonidine and Levetiracetam in Tourette Syndrome. In: Pediatric Neurology. 2009 ; Vol. 40, No. 6. pp. 420-425.
@article{4aba811f2fae4bd7bb188aee3bfeb5ff,
title = "Double-Blind, Crossover Study of Clonidine and Levetiracetam in Tourette Syndrome",
abstract = "We compared the efficacy of clonidine and levetiracetam for treating tics in Tourette syndrome. Twelve subjects were enrolled; 10 (ages 8-27 years) with moderate to moderately severe tics completed a 15-week randomized, double-blind, flexible-dose crossover protocol. Initial medication doses were clonidine (0.05 mg, twice daily) or levetiracetam (10 mg/kg/day, divided twice daily). Doses were adjusted weekly, based on telephone assessment. The primary outcome measure was baseline-to-posttreatment (6-week) change in Total Tic Score of the Yale Global Tic Severity Scale. Secondary outcome measures included total Yale Global Tic Severity Scale and Clinical Global Impression scores and behavioral measures. The mean Total Tic Score improved significantly from baseline to posttreatment with clonidine (25.2 versus 21.8) compared with levetiracetam (22.7 versus 23.6) (P = 0.013). The mean total Yale Global Tic Severity Scale and Clinical Global Impression score did not change. For levetiracetam, no changes occurred in any scales. No significant change occurred in any secondary behavioral outcome measures for either group. The most commonly reported side effects were, for clonidine, sedation (n = 5), and for levetiracetam, irritability (n = 4). Treatment with clonidine, but not levetiracetam, resulted in a small reduction in Total Tic Score, with an effect size of 0.57.",
author = "Erika Finanger and Morris, {Christina M.} and Singer, {Harvey S.}",
year = "2009",
month = "6",
doi = "10.1016/j.pediatrneurol.2008.12.014",
language = "English (US)",
volume = "40",
pages = "420--425",
journal = "Pediatric Neurology",
issn = "0887-8994",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Double-Blind, Crossover Study of Clonidine and Levetiracetam in Tourette Syndrome

AU - Finanger, Erika

AU - Morris, Christina M.

AU - Singer, Harvey S.

PY - 2009/6

Y1 - 2009/6

N2 - We compared the efficacy of clonidine and levetiracetam for treating tics in Tourette syndrome. Twelve subjects were enrolled; 10 (ages 8-27 years) with moderate to moderately severe tics completed a 15-week randomized, double-blind, flexible-dose crossover protocol. Initial medication doses were clonidine (0.05 mg, twice daily) or levetiracetam (10 mg/kg/day, divided twice daily). Doses were adjusted weekly, based on telephone assessment. The primary outcome measure was baseline-to-posttreatment (6-week) change in Total Tic Score of the Yale Global Tic Severity Scale. Secondary outcome measures included total Yale Global Tic Severity Scale and Clinical Global Impression scores and behavioral measures. The mean Total Tic Score improved significantly from baseline to posttreatment with clonidine (25.2 versus 21.8) compared with levetiracetam (22.7 versus 23.6) (P = 0.013). The mean total Yale Global Tic Severity Scale and Clinical Global Impression score did not change. For levetiracetam, no changes occurred in any scales. No significant change occurred in any secondary behavioral outcome measures for either group. The most commonly reported side effects were, for clonidine, sedation (n = 5), and for levetiracetam, irritability (n = 4). Treatment with clonidine, but not levetiracetam, resulted in a small reduction in Total Tic Score, with an effect size of 0.57.

AB - We compared the efficacy of clonidine and levetiracetam for treating tics in Tourette syndrome. Twelve subjects were enrolled; 10 (ages 8-27 years) with moderate to moderately severe tics completed a 15-week randomized, double-blind, flexible-dose crossover protocol. Initial medication doses were clonidine (0.05 mg, twice daily) or levetiracetam (10 mg/kg/day, divided twice daily). Doses were adjusted weekly, based on telephone assessment. The primary outcome measure was baseline-to-posttreatment (6-week) change in Total Tic Score of the Yale Global Tic Severity Scale. Secondary outcome measures included total Yale Global Tic Severity Scale and Clinical Global Impression scores and behavioral measures. The mean Total Tic Score improved significantly from baseline to posttreatment with clonidine (25.2 versus 21.8) compared with levetiracetam (22.7 versus 23.6) (P = 0.013). The mean total Yale Global Tic Severity Scale and Clinical Global Impression score did not change. For levetiracetam, no changes occurred in any scales. No significant change occurred in any secondary behavioral outcome measures for either group. The most commonly reported side effects were, for clonidine, sedation (n = 5), and for levetiracetam, irritability (n = 4). Treatment with clonidine, but not levetiracetam, resulted in a small reduction in Total Tic Score, with an effect size of 0.57.

UR - http://www.scopus.com/inward/record.url?scp=65449137478&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65449137478&partnerID=8YFLogxK

U2 - 10.1016/j.pediatrneurol.2008.12.014

DO - 10.1016/j.pediatrneurol.2008.12.014

M3 - Article

VL - 40

SP - 420

EP - 425

JO - Pediatric Neurology

JF - Pediatric Neurology

SN - 0887-8994

IS - 6

ER -